This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wierzbicki, A. Search for Related Content PubMed PubMed Citation Articles by Wierzbicki, A. Social Bookmarking                   What's this?

Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus

Department of Chemical Pathology, Guy's, King's and St. Thomas' Medical School (King's College London), St. Thomas' Hospital Campus, London, UK; Department of Chemical Pathology, St. Thomas' Hospital, Lambeth Palace Road, London SEl 7EH, UK Tel: (44)17l 928 9292X2027; Fax: (44)17l 928 4226; anthony.wierzbicki{at}kcl.ac.uk

Systemic lupus erythematosus is commonly associated with early onset cardiovascular disease and is often associated with hyperlipidaemia. This review examines the evidence for an increased prevalence of both CHD and hyperlipidaemia in SLE and mechanisms by which autoimmunity in SLE could accelerate the progression of atheroma. It postulates how lipid lowering therapies used in cardiological disease might help reduce the incidence of CHD in SLE.

Key Words: systemic lupus erythematosus • atherosclerosis • cardiovascular disease • lipids • apolipoproteins

Lupus, Vol. 9, No. 3, 194-201 (2000)
DOI: 10.1191/096120300678828235


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Negron, M. Molina, A. Mayor, V. Rodriguez, and L. Vila Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico Lupus, April 1, 2008; 17(4): 348 - 354. [Abstract] [PDF]

				T. K. Tso, W.-N. Huang, H.-Y. Huang, and C.-K. Chang Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus Rheumatology, September 1, 2006; 45(9): 1148 - 1153. [Abstract] [Full Text] [PDF]

				N Espinola-Zavaleta, E Alexanderson-Rosas, N Granados, M E. Soto, and M-C Amigo Myocardial perfusion defects in patients with autoimmune diseases: a prospective study. Analysis of two diagnostic tests Lupus, January 1, 2006; 15(1): 38 - 43. [Abstract] [PDF]

				S. L. Nuttall, S. Heaton, M. K. Piper, U. Martin, and C. Gordon Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia Rheumatology, June 1, 2003; 42(6): 758 - 762. [Abstract] [Full Text] [PDF]

				F Formiga, J F Meco, X Pinto, J Jacob, I Moga, and R Pujol Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients Lupus, May 1, 2001; 10(5): 359 - 363. [Abstract] [PDF]

				A S Wierzbicki Lipid-lowering drugs in lupus: an unexplored therapeutic intervention Lupus, March 1, 2001; 10(3): 233 - 236. [Abstract] [PDF]